Unerwünschte kardiovaskuläre Wirkungen von Psychopharmaka

Übersicht AMT
Unerwünschte kardiovaskuläre
Wirkungen von Psychopharmaka
Pathophysiologie und Risikominimierung
Katharina Wenzel-Seifert, Regensburg, Claus-Peter Ostermeier, Werneck, Nagia Ben Omar und
Ekkehard Haen, Regensburg, für die Arbeitsgemeinschaft Arzneimittel­therapie bei psychiatrischen
Erkrankungen (AGATE e. V.)
Literatur
1. Agus ZS. Hypomagnesemia. J Am Soc Nephrol 1999;10:616–22.
2. Alvarez P, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010;5:97–104.
3. Antzelevitch C. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 2007;9(Suppl 4):iv4–15.
Epub 2007 Nov 21.
4. Arizona CERT. QT Drug Lists by Risk Groups. http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm (Zugriff am 15.06.2013).
5. Arzneimittelkommission der Deutschen Ärzteschaft. Information über
die Änderung der bisher empfohlenen Applikationswege von Haldol®Janssen Injektionslösung. AkdÄ Drug Safety Mail 2010. http://www.
akdae.de/Arzneimittelsicherheit/DSM/Archiv/2010-098.html (Zugriff am
15.06.2013).
6. Astrom-Lilja C, Odeberg JM, Ekman E, Hägg S. Drug-induced torsades de
pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 2008;17:587–92.
7. Azene EM, Xue T, Li RA. Molecular basis of the effect of potassium
on heterologously expressed pacemaker (HCN) channels. J Physiol
2003;547:349–56. Epub 2003 Feb 04.
8. Banov M, Tohen M, Friedberg J. High risk of eosinophilia in women treated with cloza­pine. J Clin Psychiatry 1995;54:466–9.
9. Barak Y, Swartz M, Levy D, Weizman R. Age-related differences in the
side effect profile of citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:545–8. Epub 2003 Apr 15.
10.Berkelhammer C, Bear R. A clinical approach to commen electrolyte
problems: 4. Hypomagnesemia. Can Med Assoc J 1985;132:360–8.
11.Beyenburg S, Schonegger K. Severe bradycardia in a stroke patient
caused by a single low dose of escitalopram. Eur Neurol 2007;57:50–1.
Epub 2006 Nov 23.
12.Bogdanov KY, Vinogradova TM, Lakatta EG. Sinoatrial nodal cell ryanodine receptor and Na+-Ca2+ exchanger: molecular partners in pacemaker
regulation. Circ Res 2001;88:1254–8. Epub 2001 Jun 23.
13.Butany J, Ahn E, Luk A. Drug-related cardiac pathology. J Clin Pathol
2009;62:1074–84. Epub 2009 Dez 01.
14.Carnahan RM, Lund BC, Perry PJ, Pollock BG, et al. The anticholinergic drug scale as a measure of drug-related anticholinergic burden:
associations with serum anticholinergic activity. J Clin Pharmacol
2006;46:1481–6. Epub 2006 Nov 15.
15.Castro VM, Clements CC, Murphy SN, Gainer VS, et al. QT interval and
antidepressant use: a cross sectional study of electronic health records.
BMJ 2013;346:f288. DOI: 10.1136/bmj.f288. Epub 2013 Jan 31.
16.Chew ML, Mulsant BH, Pollock BG, Lehman ME, et al. Anticholinergic
activity of 107 medications commonly used by older adults. J Am Geriatr
Soc 2008;56:1333–41. Epub 2008 May 31.
17.Cohn J, Kowey P, Whelton P, Prisant L. New guidelines for potassium
replacement in clinical practice. A contemperary review by the national
council on potassium in clinical practice. Arch Int Med 2000;160:2429–
36.
18.Couderc JP, Xiaojuan X, Zareba W, Moss AJ. Assessment of the stability of
the individual-based correction of QT interval for heart rate. Ann Noninvasive Electrocardiol 2005;10:25–34. Epub 2005 Jan 15.
19.Coulter D, Bate A, Mayboom R, Lindquist M, et al. Antipsychotic drugs
and heart muscle disorder in international parmacovigilance: data min­
ing study. BMJ 2001;62:191–8.
20.DePonti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-anti-arrhythmic
drugs: a call for consensus. Eur J Clin Pharmacol 2001;57:185–209.
21.Druteika D, Zed PJ. Cardiotoxicity following bupropion overdose. Ann
Pharmacother 2002;36:1791–5. Epub 2002 Oct 26.
22.Eap CB, Crettol S, Rougier JS, Schlapfer J, et al. Stereoselective block
of hERG channel by (S)-methadone and QT interval prolongation in
CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007;81:719–28. Epub
2007 Mar 03.
23.Eckhardt LL, Rajamani S, January CT. Protein trafficking abnormalities:
a new mechanism in drug-induced long QT syndrome. Br J Pharmacol
2005;145:3–4. Epub 2005 Feb 16.
24.FDA. Information for Healthcare Professionals: Haloperidol (marketed
as Haldol, Haldol Decanoate and Haldol Lactate). FDA ALERT 9/2007.
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm. (Zugriff am 15.06.2013).
25.FDA. FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celax® (citalopram hydrochloride). FDA Drug
Safety Communication 24.8.2011.http://www.fda.gov/Drugs/DrugSafety/
ucm269086.htm (Zugriff am 15.06.2013).
26.FDA. Stimulant medications used in children with attention-deficit/hyperactivity disorder – Communication about an ongoing review. FDA
drug safety communications 12.12.2011. http://www.fda.gov/Drugs/
DrugSafety/ucm277770.htm. (Zugriff am 15.06.2013).
27.FDA. Safety review of medications used to treat attention-deficit/hyperactivity disorder (ADHD) in adults. FDA drug safety communications
12.12.2011. http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm (Zugriff am 15.06.2013).
28.FDA Center for Drug Evaluation and Research. Approval package for Celexa: Interdisciplinary Review Team for QT Studies Consultation: Thorough QT Study Review. 12. August 2011. S. 77–104. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020822Orig1s038s040_021046Or
ig1s016s017Rev.pdf [77–104] (Zugriff am 15.06.2013).
29.Feinstein RE. Cardiovascular effects of novel antipsychotic medications.
Heart Dis 2002;4:184–90. Epub 2002 May 25.
30.Florian J, Garnett CE, Nallani SC, Rappaport BA, et al. A modeling and
simulation approach to characterize methadone QT prolongation using
pooled data from five clinical trials in MMT patients. Clin Pharmacol
Ther 2012;91:666–72. Epub 2012 Mar 02.
31.Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on
the QTc interval. Experts Opin Pharmacother 2002;3:479–98.
32.Haas SJ, Hill R, Krum H, Liew D, et al. Clozapine-associated myocarditis:
a review of 116 cases of suspected myocarditis associated with the use of
clozapine in Australia during 1993–2003. Drug Saf 2007;30:47–57. Epub
2006 Dec 30.
33.Haddad P, Anderson I. Antipsychotic-related QTc prolongation, torsade
de pointes and sudden death. Drugs 2002;62:1649–71.
34.Haverkamp H, Deuschle M. Antipsychotikainduzierte QT-Verlängerung.
Nervenarzt 2006;77:276–88.
Dr. med. Katharina Wenzel-Seifert, Nagia Ben Omar, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, Klinische Pharmakologie am Lehrstuhl mit Poli­klinik für Psychiatrie und
Psychotherapie der Universität Regensburg, Universitätsstraße 84, 93053 Regensburg,
E‑Mail: [email protected]
Claus-Peter Ostermeier, Krankenhaus für Psych­iatrie, Psychotherapie und Psychosomatische Medizin Schloss Werneck, Balthasar-Neumann-Platz 1, 97440 Werneck
Arzneimitteltherapie 31. Jahrgang · Heft 11 · 2013 *1
AMT Übersicht
35.Hiemke C, Bauman P, Bergemann N, Conca A, et al. AGNP-KonsensusLeitlinien für therapeutisches Drug-Monitoring in der Psych­iatrie: Update 2011. Psychopharmakotherapie 2012;19:91–122.
36.Hoffmann P, Warner B. Are hERG-channel inhibition and QT interval
prolongation all there is in drug-induced torsadogenesis? A review of
emerging trends. J Pharmacol Toxicol Methods 2006;53:87–105. Epub
Date 2005 Nov 18.
37.Howell C, Wilson AD, Waring WS. Cardio­vas­cular toxicity due to venlafaxine poison­ing in adults: a review of 235 consecutive cases. B J Clin
Pharmacol 2007;64:192–7. Epub 2007 Feb 15.
38.Hsu C, Liu P, Chen J, Yeh T, et al. Electrocardiographic abnormalities as
predictors for over-range lithium levels. Cardiology 2005;103:101–6.
39.Ide A, Kamijo Y. Intermittent complete atrio­ventricular block after long
term low-dose carbamazepine therapy with a serum concentration less
than the therapeutic level. Intern Med 2007;46:627–9. Epub 2007 May
03.
40.Iqbal M, Rahman A, Husain Z, Mahmud S, et al. Clozapine: A clinical review of adverse effects and management. Ann Clin Psychiatry
2003;15:33–48.
41.Justo D, Prokhorov V, Heller K, Zeltser D. Torsade de pointes induced by
psychotropic drugs and the prevalence of its risk factors. Acta Psychiat
Scand 2005;111:171–6. Epub 2005 Feb 11.
42.Kandan SR, Saha M. Severe primary hypothyroidism presenting with
torsades de ­pointes. BMJ Case Rep 2012; DOI: 10.1136/bcr.12.2011.5306.
Epub 2012 Sep 19.
43.Kiev A, Masco HL, Wenger TL, Johnston JA, et al. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin
Psychiatry 1994;6:107–15. Epub 1994 Jun 01.
44.Killian J, Kerr R, Lawrence C, Celermajer D. Myocarditis and cardiomyopathy with clozapine. Lancet 1999;354:1841–5.
45.Kleinfeld M, Borra S, Gavani S, Corcoran A. Hypokalemia: Are elderly
females more vulnerable? J Natl Med Assoc 1993;85:861–4.
46.Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, et al. Torsade de
pointes associated with very-high-dose methadone. Ann Intern Med
2002;137:501–4. Epub 2002 Sep 17.
47.Leung JYT, Barra AM, Procyshynb RM, Honerb WG, et al. Cardiovascular
side-effects of antipsychotic drugs: The role of the autonomic nervous
system. Pharmacol Ther 2012;135:113–22.
48.Lilly Deutschland GmbH. Risiko eines Blutdruck- und Herzfrequenzanstiegs. Rote-Hand-Brief zu Strattera® (Atomoxetin) 07.12.2011. www.
bfarm.de/DE/Pharmakovigilanz/risikoinfo/2011/rhb-strattera.html (Zugriff am 15.06.2013).
49.Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil,
rivastigmine and galantamine for patients with Alzheimer’s disease:
systematic review of the „real-world“ evidence. Dement Geriatr Cogn
Disord 2009;28:389–403. Epub 2009 Nov 07.
50.Lundbeck GmbH. Zusammenhang von Escitalopram (Cipralex®) mit
dosisabhängiger QT-Intervall-Verlängerung. Rote-Hand-Brief zu Escitalopram (Cipralex®) 5. Oktober 2011. http://www.bfarm.de/DE/Pharmakovigilanz/risikoinfo/Archiv/2011/rhb-cipralex.html (Zugriff am 15.06.2013).
51.Lundbeck GmbH. Zusammenhang von Cipramil® (Citalopramhydrobromid /Citalopramhydrochlorid) mit dosisabhängiger QT-Intervallverlängerung. Rote-Hand-Brief zu Cipramil® (Citalopram). 31. Oktober 2011.
http://www.bfarm.de/DE/Pharmakovigilanz/risikoinfo/Archiv/2011/rhbcipramil.html (Zugriff am 15.06.2013).
52.Mackin P. Cardiac side effects of psychiatric drugs. Human Psychopharmacol Clin Exp 2008;23:3–14.
53.Mayet S, Gossop M, Lintzeris N, Markides V, et al. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram
and what is the prevalence of QTc prolongation? Drug Alcohol Rev
2011;30:388–96. Epub 2011 Maerz 02.
54.McKnight RF, Adida M, Budge K, Stockton S, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379:721–8. Epub
2012 Jan 24.
55.Merrill D, Dec G, Goff D. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005;25:32–41.
56.Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how
should institutions respond? J Hosp Med 2010;5:E8–16. Epub 2010 Apr
16.
57.Mitcheson JS. hERG potassium channels and the structural basis of druginduced arrhythmias. Chem Res Toxicol 2008;21:1005–10. Epub 2008
May 02.
58.Novartis. Association of Clozaril (clozapine) with cardiovasculr toxicity.
Dear Healthcare Professional Letter. 14.01.2002. http://www.canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2002/14697a-eng.php
(Zugriff am 15.06.2013).
59.Offerman SR, Alsop JA, Lee J, Holmes JF. Hospitalized lithium overdose cases reported to the California Poison Control System. Clin Toxicol
2010;48:443–8. Epub 2010 Jun 03.
*2
Arzneimitteltherapie 31. Jahrgang · Heft 11 · 2013 60.Oka H, Yoshioka M, Onouchi K, Morita M, et al. Characteristics of orthostatic hypotension in Parkinson’s disease. Brain 2007;130:2425–32.
61.Oudit GY, Korley V, Backx PH, Dorian P. Lithium-induced sinus node
disease at therapeutic concentrations: linking lithium-induced block­
ade of sodium channels to impaired pacemaker activity. Can J Cardiol
2007;23:229–32. Epub 2007 Mar 10.
62.Ozeki Y, Fujii K, Kurimoto N, Yamada N, et al. QTc prolongation and antipsychotic medications in a sample of 1,017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:401–5.
63.Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns? Curr Pharm Des
2004;10:2463–75.
64.Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of
competing medications for adults with attention-deficit hyperactivity
disorder: a systematic review and indirect comparison meta-analysis.
Psychopharmacology 2008;197:1–11. Epub 2007 Nov 21.
65.Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de
pointes: data min­ing of the public version of the FDA Adverse Event
Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009;18:512–8.
66.Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, et al. Task Force
on Sudden Cardiac Death, European Society of Cardiology. Europace
2002;4:3–18.
67.Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, et al. Drug-induced
long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 2006;149:481–9.
Epub 2006 Sep 13.
68.Rastergar A, Soleimani M. Hypokal­aemia and hyperkalaemia. Postgrad
Med J 2001;77:759–64.
69.Reddy S, Hui D, El Osta B, de la Cruz M, et al. The effect of oral metha­
done on the QTc interval in advanced cancer patients: a prospective
pilot study. J Palliat Med 2010;13:33–8.
70.Roesch-Ely D, Van Einsiedel R, Kathofer S, Schwaninger M, et al. Myocarditis with quetiapine. Am J Psychiatry 2002;159:1607–8.
71.Roose SP, Glassman AH, Giardina EG, Walsh BT, et al. Tricyclic antidepressants in depressed patients with cardiac conduction dis­ease. Arch
Gen Psychiatry 1987;44:273–5. Epub 1987 Mar 01.
72.Roose SP, Dalack GW, Glassman AH, Woodring S, et al. Cardiovascular
effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991;148:512–6. Epub 1991 Apr 01.
73.Sala M, Vicentini A, Brambilla P, Montomoli C, et al. QT interval prolongation related to psychoactive drug treatment: a comparison
of monotherapy versus polytherapy. Ann Gen Psychiatry 2005;4:1.
DOI:10.1186/1744–859X-4–1,
74.Schömig H, Ritz E, Stein G. Elektrolyt- und Wasserhaushalt. In: Berdel
W, Böhm M, Classen M, Diehl V, et al. (Hrsg.). Innere Medizin. 5. Auflage.
München: Urban & Fischer, 2004: 1729–63.
75.Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol
1998;81:238–40.
76.Shojaie M, Eshraghian A. Primary hypo­thyroidism presenting with
Torsades de ­pointes type tachycardia: a case report. Cases J 2008;1:298.
Epub 2008 Nov 08.
77.Siebrands CC, Schmitt N, Friederich P. Local anesthetic interaction with
human ether-a-go-go-related gene (HERG) channels: role of aromatic
amino acids Y652 and F656. Anesthesiology 2005;103:102–12. Epub 2005
Jun 29.
78.Spallone V, Ziegler D, Freeman R, Bernardi L, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis,
and management. Diabetes Metab Res Rev 2011 Jun 23, doi: 10.1002/
dmrr.1239.
79.Spigset O. Adverse reactions of selective serotonin reuptake inhibitors:
reports from a spontaneous reporting system. Drug Saf 1999;20:277–87.
Epub 1999 Apr 30.
80.Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732–47. Epub 2005 Sep 06.
81.Stallvik M, Nordstrand B, Kristensen O, Bathen J, et al. Corrected QT interval during treatment with methadone and buprenorphine – relation
to doses and serum concentrations. Drug Alcohol Depend 2013;129:88–
93. Epub 2012 Oct 23.
82.Sterke CS, Ziere G, van Beeck EF, Looman CW, et al. Dose-response relationship between selective serotonin re-uptake inhibitors and injurious
falls: a study in nursing home residents with dementia. B J Clin Pharmacol 2012;73:812–20.
83.Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacology 2005;20:243–51.
84.Straus SM, Bleumink GS, Dieleman JP, van der Lei J, et al. Antipsychotics
and the risk of sudden cardiac death. Arch Intern Med 2004;164:1293–7.
Epub 2004 Jul 01.
Unerwünschte kardiovaskuläre Wirkungen von Psychopharmaka AMT
85.Talati SN, Aslam AF, Vasavada B. Sinus node dysfunction in association
with chronic lithium therapy: a case report and review of literature. Am
J Ther 2009;16:274–8. Epub 2009 Apr 09.
86.Tank J, Schroeder C, Diedrich A, Szczech E, et al. Selective impairment
in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation 2003;107:2949–54. Epub 2003 Jun 11.
87.Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev 2005;24:205–14. Epub 2006 Jan 05.
88.van Melick EJ, Wilting I, Meinders AE, Egberts TC. Prevalence and determinants of thyroid disorders in elderly patients with affective disorders: lithium and nonlithium patients. Am J Geriatric Psychiatry
2010;18:395–403. Epub 2010 Apr 30.
89.van Noord C, Straus S, Sturkenboom M, Hofman A, et al. Psychotropic
drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009;29:9–15.
90.Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, et al. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in
the elderly. Drugs Aging 2009;26:997–1012. Epub 2009 Nov 26.
91.Warner B, Hoffmann P. Investigation of the potential of clozapine to
cause torsade de pointes. Adverse Drug React Toxicol Rev 2002;21:189–
203.
92.Weeke P, Jensen A, Folke F, Gislason GH, et al. Antidepressant use and
risk of out-of-hospital cardiac arrest: a nationwide case-time-control
study. Clin Pharmacol Ther 2012;92:72–9. Epub 2012 May 17.
93.Weiner I, Wingo C. Hypokalemia – Consequences, causes, and correction. J Am Soc Nephrol 1997;8:179–88.
94.Wenzel-Seifert K, Haen E. Rote-Hand-Briefe zu Citalopram und Escitalo­
pram. Psychopharmakotherapie 2012;19:19–21.
95.Wenzel-Seifert K, Haen E. Kardiovaskuläres Risiko bei medikamentöser
ADHS-Behandlung. Psychopharmakotherapie 2013: im Druck.
96.Wenzel-Seifert K, Wittmann M, Haen E. Psychopharmakaassoziierte QTc-Intervall-Verlängerung und Torsade de pointes. Dtsch Ärztebl
2011;108:687–93.
97.Wernicke J, Faries D, Girod D, Brown J, et al. Cardiovascular effects of
atomoxetine in children, adolescents, and adults. Drug Saf 2003;26:729–
40.
98.Wernicke J, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled
studies. Drug Saf 2007;30:437–55.
Arzneimitteltherapie 31. Jahrgang · Heft 11 · 2013 *3